Miguel Forte – CEO, Bone Therapeutics, Belgium
Miguel Forte, CEO of Bone Therapeutics, walks through his journey leading the promising Belgian biotech company. He also shares with his view of the Belgian healthcare system and what makes…
Address: Rue de Stallestraat 63/4, B-1180 Brussels,Belgium
Tel:
Web: http://www.octapharma.com/en.html
Our Group-wide mission is the safe and optimal use of human proteins.
Octapharma respects donated human plasma as a scarce and valuable resource. We meet our Mission through the use of cutting-edge, validated viral inactivation and state-of-the-art purification technologies, in order to achieve the highest production yields and manufacture medical products with the highest possible safety margins. We respect human plasma as a sparce resource for life saving therapies.
The Octapharma portfolio focuses on protein and other biopharmaceutical products derived from human plasma, in three therapeutic areas:
Haematology
Coagulation factors to treat bleeding disorders.
Intensive Care and Emergency Medicine
Plasma and blood proteins (such as albumin) used to stabilise blood circulation, restore coagulation function, and prevent shock, e.g., for heavy burns, injuries, and in surgery.
Immunotherapy
Immunoglobulins to treat immune disorders and prevent rhesus incompatibility in pregnancies.
Miguel Forte, CEO of Bone Therapeutics, walks through his journey leading the promising Belgian biotech company. He also shares with his view of the Belgian healthcare system and what makes…
Brigitte Nolet, country manager of Roche for Belgium and Luxembourg, speaks about her transition to the Belgian market and her priorities for leading the affiliate. Nolet goes on the elaborate…
Jean Nève and Fabrice Peters, president and general coordinator of the Belgian Superior Health Council (SHC), introduce the organization, elaborate on its role in helping guide the country’s healthcare policy,…
Bertrand Duquesne, managing director of Boiron Belgium, elaborates on the challenges being faced by homeopathy manufacturers in western Europe and explains how the company and its peers are create dialogue…
Vincent Verschraegen, country manager of Mylan Belgium and Luxembourg, speaks about his onboarding in the company and what attracted him to join the organization. Verschraegen also discusses Mylan’s evolution from…
PDC*Line Pharma’s Eric Halioua introduces the Belgian immuno-oncology biotech, its clinical-stage assets, the impact of the firm’s collaboration with Korean LG Chem, and future internationalisation strategies. As a multicultural…
Miranda Heining, general manager of Fresenius Kabi for Belgium and the Netherlands, speaks about the career path that led her to join the pharma industry and lead the affiliate, her…
Christos Andriopoulos, managing director of Merck, speaks about his experience transitioning from global operations to leading a country subsidiary. Andriopoulos goes on to explain the company’s unique positioning as an…
Fréderic Covemaeker, general manager of Nordic Pharma Belgium, introduces the Belgian affiliate which he established himself in 2008 and elaborates on the next stage of development for operations as Nordic…
Despite a population size of only 11.4 million (ninth in Europe), Belgium is the continent’s fifth biggest spender on R&D, behind only Germany, Switzerland, the UK, and France according to…
Xavier De Cuyper introduces the Federal Agency for Medicines & Health Products (FAMHP) and the essential role it plays in Belgium’s healthcare regulatory framework since being founded in 2007. De…
Chantal Depondt, president of the Belgian Neurological Society (BNS), introduces the mission of the professional association and offers her insights into the healthcare and research dynamics surrounding neurological diseases. Depondt…
See our Cookie Privacy Policy Here